Literature DB >> 24515598

Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension.

Deepa M Gopal1, Bryan Doldt, Kim Finch, Robert W Simms, Harrison W Farber, Noyan Gokce.   

Abstract

OBJECTIVE: Systemic sclerosis (SSC; scleroderma)-associated pulmonary arterial hypertension (PAH) is a major cause of mortality in SSc patients and represents an important diagnostic and therapeutic target. Our aims were to evaluate the relationship between echocardiogram-derived right-sided heart hemodynamics and gold standard right-sided heart catheterization (RHC) measurements in a scleroderma population and to investigate whether this relationship is modified by a subset of pulmonary hypertension.
METHODS: We performed RHC and echocardiography on the same day, with pulmonary function testing in 21 consecutive subjects with scleroderma and precapillary pulmonary hypertension (mean ± SD age 57 ± 10 years, 81% women).
RESULTS: RHC measures, including pulmonary arterial systolic and mean pressure and pulmonary vascular resistance (PVR), correlated strongly with echocardiogram-derived data. RHC-derived PVR was negatively associated with right ventricular (RV) systolic performance, as measured by tricuspid annular plane systolic excursion (TAPSE; rho = -0.70, P < 0.001), tissue Doppler tricuspid s' velocity (rho = -0.68, P = 0.002), and RV fractional area change (rho = -0.78, P < 0.001). Correlations with TAPSE and s' velocity were strengthened when forced vital capacity %/diffusing capacity of the lung for carbon monoxide % ≥1.6 was used to identify pure PAH phenotypes in SSc. Bland-Altman analyses demonstrated strong agreement between RHC and echocardiogram-derived hemodynamic measures.
CONCLUSION: Our findings suggest that echocardiography may play a clinical role in identifying pulmonary hypertension and RV dysfunction noninvasively, particularly in a subset of SSc patients stratified by pulmonary function testing. This method may establish specific disease phenotypes with differential cardiovascular impact and prove useful as a marker of disease progression/risk stratification in SSC patients that warrants further investigation in larger cohorts.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 24515598      PMCID: PMC4204737          DOI: 10.1002/acr.22307

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  24 in total

1.  Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis.

Authors:  C P Denton; J B Cailes; G D Phillips; A U Wells; C M Black; R M Bois
Journal:  Br J Rheumatol       Date:  1997-02

Review 2.  Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.

Authors:  Sergio A Jimenez; Chris T Derk
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

3.  Tricuspid annular systolic velocity: a useful measurement in determining right ventricular systolic function regardless of pulmonary artery pressures.

Authors:  Neil Saxena; Navin Rajagopalan; Kathy Edelman; Angel López-Candales
Journal:  Echocardiography       Date:  2006-10       Impact factor: 1.724

4.  Tricuspid annular displacement predicts survival in pulmonary hypertension.

Authors:  Paul R Forfia; Micah R Fisher; Stephen C Mathai; Traci Housten-Harris; Anna R Hemnes; Barry A Borlaug; Elzbieta Chamera; Mary C Corretti; Hunter C Champion; Theodore P Abraham; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2006-08-03       Impact factor: 21.405

5.  Isolated diffusing capacity reduction in systemic sclerosis.

Authors:  V D Steen; G Graham; C Conte; G Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-07

6.  Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.

Authors:  Salim Trad; Zahir Amoura; Catherine Beigelman; Julien Haroche; Nathalie Costedoat; Le Thi Huong Du Boutin; Patrice Cacoub; Camille Frances; Bertrand Wechsler; Philippe Grenier; Jean-Charles Piette
Journal:  Arthritis Rheum       Date:  2006-01

7.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.

Authors:  Virginia Steen; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2003-02

8.  Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis.

Authors:  D Mukerjee; D St George; C Knight; J Davar; A U Wells; R M Du Bois; C M Black; J G Coghlan
Journal:  Rheumatology (Oxford)       Date:  2004-01-06       Impact factor: 7.580

9.  A simple method for noninvasive estimation of pulmonary vascular resistance.

Authors:  Amr E Abbas; F David Fortuin; Nelson B Schiller; Christopher P Appleton; Carlos A Moreno; Steven J Lester
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

10.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  5 in total

Review 1.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 2.  Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.

Authors:  Yasushi Tsujimoto; Junji Kumasawa; Sayaka Shimizu; Yoshio Nakano; Yuki Kataoka; Hiraku Tsujimoto; Michihiko Kono; Shinji Okabayashi; Haruki Imura; Takahiro Mizuta
Journal:  Cochrane Database Syst Rev       Date:  2022-05-09

3.  Prognostic value of three-dimensional echocardiographic right ventricular ejection fraction in patients with pulmonary arterial hypertension.

Authors:  Mitsushige Murata; Toshimitsu Tsugu; Takashi Kawakami; Masaharu Kataoka; Yugo Minakata; Jin Endo; Hikaru Tsuruta; Yuji Itabashi; Yuichiro Maekawa; Mitsuru Murata; Keiichi Fukuda
Journal:  Oncotarget       Date:  2016-12-27

4.  SAPHIRE: Stress and Pulmonary Hypertension in Rheumatoid Evaluation-A Prevalence Study.

Authors:  G E M Reeves; N Collins; P Hayes; J Knapp; M Squance; H Tran; B Bastian
Journal:  Int J Rheumatol       Date:  2016-04-20

5.  Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease.

Authors:  Karolina Niklas; Arkadiusz Niklas; Tatiana Mularek-Kubzdela; Mariusz Puszczewicz
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.